en · de · es
sr9009-notes.peptides7501.com › Data › Background And Mechanism Of Sr9009 — Evidence Review

Background And Mechanism Of Sr9009 — Evidence Review

By Editorial Desk · published 2026-01-09 · last reviewed 2026-02-27 · Data

A practical reference on storage stability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-02-27. Anything still debated is marked as such rather than presented as settled.

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Analytical Detection and Regulatory Status

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule ligand; not a hormone or peptide
Molecular formulaC20H24ClN3O4SReported for the free base
CAS Registry Number1379686-30-2Unique chemical identifier
Common synonymsSR9009; stenabolicStenabolic is informal and not an official name
Reported targetsREV-ERBα and REV-ERBβNuclear receptors linked to circadian and metabolic regulation

Background and Pharmacological Mechanism

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Related pages on this site

Identity, Handling, and Regulation

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Handling Storage and Quality Control

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Reference notes

== Platelet membrane glycoproteins == Platelet membrane glycoproteins, mainly GPIa/IIa, GPVI and probably GPIV as well, function as receptors engaged in platelet adhesion to collagen. The leading role in the elimination of high-stress injury is taken by the glycoprotein Ib-IX-V complex.

=== "Inflammaging" === "Inflammaging" refers a chronic, sterile, low-grade inflammation that develops with advanced age. It affects the start and progression of diseases that occur due to aging, e.g. type 2 diabetes. It occurs in the skin because when exposed to UV radiation, it damages the epidermal cells, which in turn causes inflammation to occur.

Indium is a chemical element; its symbol is In and its atomic number is 49. It is a silvery-white post-transition metal and one of the softest elements. Chemically, indium is similar to gallium and thallium, and its properties are largely intermediate between the two. It was discovered in 1863 by Ferdinand Reich and Hieronymous Theodor Richter by spectroscopic methods and named for the indigo blue line in its spectrum. Indium is used primarily in the production of flat-panel displays as indium tin oxide (ITO), a transparent and conductive coating applied to glass. It is also used in the semiconductor industry, in low-melting-point metal alloys such as solders and soft-metal high-vacuum seals. It is used in the manufacture of blue and white LED circuits, mainly to produce Indium gallium nitride p-type semiconductor substrates. It is produced exclusively as a by-product during the processing of the ores of other metals, chiefly from sphalerite and other zinc sulfide ores. Indium has no biological role and its compounds are toxic when inhaled or injected into the bloodstream, although they are poorly absorbed following ingestion. Indium has no metabolic role in any organism that has been studied.

== January 31, 1982 (Sunday) == The documentary Let Poland be Poland was televised around the world and reportedly watched by 185,000,000 in 50 nations. Hosted by Charlton Heston in the U.S., the show included appearances by Paul McCartney, Orson Welles, Henry Fonda, Kirk Douglas, Max von Sydow, James A. Michener, Glenda Jackson, Madeleine Albright and the song "Ever Homeward", sung by Frank Sinatra. The show also featured recorded segments from world leaders, including U.S. President Ronald Reagan, UK Prime Minister Margaret Thatcher, German Chancellor Helmut Schmidt, Japanese premier Zenkō Suzuki, French President François Mitterrand, and prime ministers Pierre Trudeau (Canada), Arnaldo Forlani (Italy), Adolfo Suárez (Spain), Kåre Willoch (Norway), Bülend Ulusu (Turkey), Francisco Pinto Balsemão (Portugal), Wilfried Martens (Belgium), Pierre Werner (Luxembourg) and Gunnar Thoroddsen (Iceland). The Statute of Autonomy of the Principality of Asturias went into effect, recognizing the right of self-government of the Spanish region of 78 municipalities in areas formerly occupied by the medieval Kingdom of Asturias, including the capital, Oviedo. Spain's province of Santander was renamed Cantabria

Sources: en.wikipedia.org

Reference notes

== Utility in prediction == The utility of the criteria in determining the prognosis of patients with acute liver failure is defined by their operating characteristics. The positive predictive value of the criteria in predicting death from acute liver failure has ranged from 70% to 100%. A Canadian meta-analysis assessing various prognostic indices found that the specificity of the King's College criteria in predicting mortality exceeded 90%, with a sensitivity of 69%. As a result, the American Society for Study of Liver Diseases has recommended the King's College Criteria as being helpful early parameters in ascertaining the need for liver transplantation in patients with acute liver failure.

The parenteral route is any route that is not enteral (par- + enteral). Parenteral administration can be performed by injection, that is, using a needle (usually a hypodermic needle) and a syringe, or by the insertion of an indwelling catheter. Locations of application of parenteral administration include:

In the cytosol, acetyl-CoA carboxylase (ACC) generates malonyl-CoA from acetyl-CoA and CO2 and is responsible for the majority of the cellular malonyl-CoA pool. The amount of malonyl-CoA in the cytosol is tightly regulated by the opposing activities of ACC and malonyl-CoA decarboxylase (MCD), which catalyzes the reverse reaction to produce acetyl-CoA and CO2. Cytosolic malonyl-CoA plays a key role in regulating fatty acid metabolism. Although malonyl-CoA itself cannot enter mitochondria, malonate produced through non-enzymatic hydrolysis of cytosolic malonyl-CoA may cross membranes and contribute to the mitochondrial malonyl-CoA pool. In mitochondria, the malonyl-CoA pool is generated by acyl-CoA synthetase family member 3 (ACSF3), which catalyzes the thioesterification of malonate and CoA, and by a mitochondrial isoform of acetyl-CoA carboxylase 1 (mtACC1), which produces malonyl-CoA through the carboxylation of acetyl-CoA and CO2. Complementing these synthetic activities, MCD likeweise operates in mitochondria, where it converts malonyl-CoA back to acetyl-CoA and CO2. Mitochondrial malonyl‑CoA is essential for local protein malonylation as well as for mitochondrial fatty acid synthesis (mtFAS). In the nucleus, malonyl-CoA is synthesized by ACC1, which is mainly cytoplasmic, suggesting a local and possibly unconventional function. The extent of malonylation increases with malonyl‑CoA availability particularly under conditions such as metabolic stress or enzyme deficiencies, for example malonyl‑CoA decarboxylase deficiency.

Sources: en.wikipedia.org

Notes from published material

==== Sun drying ==== This preservation method is most economical out of all methods. The tempeh can be blanched prior to dehydration to preserve flavor and prolong shelf life. Tempeh is exposed to internal solar dryer temperature of 80–90 °C (180–200 °F) in this method. A disadvantage of this method is that sunlight can destroy some of the vitamin B12 of tempeh.

===== MeSH D08.811.520.224 – carbon-carbon lyases (EC 4.1) ===== MeSH D08.811.520.224.062 – aldehyde lyases MeSH D08.811.520.224.062.250 – 2-dehydro-3-deoxyphosphoheptonate aldolase MeSH D08.811.520.224.062.400 – fructose-bisphosphate aldolase MeSH D08.811.520.224.125 – carboxy-lyases MeSH D08.811.520.224.125.050 – adenosylmethionine decarboxylase MeSH D08.811.520.224.125.100 – aromatic-L-amino-acid decarboxylase MeSH D08.811.520.224.125.100.500 – dopa decarboxylase MeSH D08.811.520.224.125.250 – glutamate decarboxylase MeSH D08.811.520.224.125.300 – histidine decarboxylase MeSH D08.811.520.224.125.350 – indole-3-glycerol-phosphate synthase MeSH D08.811.520.224.125.387 – methylmalonyl-coa decarboxylase MeSH D08.811.520.224.125.425 – ornithine decarboxylase MeSH D08.811.520.224.125.450 – orotidine-5'-phosphate decarboxylase MeSH D08.811.520.224.125.500 – phosphoenolpyruvate carboxykinase (atp) MeSH D08.811.520.224.125.550 – phosphoenolpyruvate carboxykinase (gtp) MeSH D08.811.520.224.125.650 – phosphoenolpyruvate carboxylase MeSH D08.811.520.224.125.750 – pyruvate decarboxylase MeSH D08.811.520.224.125.800 – ribulose-bisphosphate carboxylase MeSH D08.811.520.224.125.875 – tyrosine decarboxylase MeSH D08.811.520.224.125.900 – uroporphyrinogen decarboxylase MeSH D08.811.520.224.187 – deoxyribodipyrimidine photo-lyase MeSH D08.811.520.224.600 – oxo-acid-lyases MeSH D08.811.520.224.600.200 – anthranilate synthase MeSH D08.811.520.224.600.700 – isocitrate lyase MeSH D08.811.520.224.800 – tryptophanase MeSH D08.811.520.224.900 – tyrosine phenol-lyase

That's why they're stuck where they are.'" Kingsolver said that she resented all parts of Hillbilly Elegy, feeling that Vance was not from Appalachia and did not understand the community. Following Hillbilly Elegy, a surge in publishing from marginalized communities in Appalachia began as an effort to counter stereotypes of the region by sharing a wider range of more nuanced stories. They were motivated by broadening narratives about Appalachia to counter longstanding national stereotypes about the region, which they attributed both to Hillbilly Elegy's recent popularity and widespread biases. Haymarket Books, Hub City Press, West Virginia University Press, and University Press of Kentucky led concerted efforts to publish more diverse writing about the region. University Press of Kentucky's Appalachian Futures series explicitly sought to give "voice to Black, Native, Latinx, Asian, Queer, and other nonwhite or ignored identities within the Appalachian region". Its first book, Tar Hollow Trans, was published in 2023.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Is SR9009 approved for human use?

No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.

How does SR9009 differ from natural REV-ERB ligands?

Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.

Is SR9009 approved for human use?

No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.

Network